| Objective：To investigate the relationship between the polymorphismsof MTHFR, GSTP1,ERCC1and the response to FOLFOX chemotherapy inadvanced colorectal cancer.Methods：A total of150patients diagnosed as an advanced colorectalcancer by the pathology were treated with FOLFOX chemotherapy andDNA of peripheral blood-leukocytes was obtained before the treatment,MTHFR,GSTP1,ERCC1genetype were detected by theHRM-SNP method.Results：(1)The frequencies of MTHFR429Glu/Glu, Glu/Ala, Ala/Alawere59.1%,37.0%,3.9%; MTHFR222Ala/Ala, Ala/Val, Val/Val were12.6%,47.2%,40.1%;GSTP1-105Ile/Ile,Ile/Val,Val/Val genetypes were63.0%,33.1%,3.9%;ERCC1-118AA,AT,TT genetypes were50.4%,41.7%,7.9%,respectively.(2)The effective rate of FOLFOX chemotherapy amongpatients with GSTP1-105Ile/Ile,Ile/Val+Val/Val genetypes were19.7%,20.5%,OR=2.876,95%CI(1.288,6.424),P<0.05; MTHFR222Ala/Ala,Ala/Val+Val/Val genetypes were11.8%,28.3%, OR=2.236,95%CI(1.020,5.017),P<0.05,respectively,which was a significant difference.Conclusion： the polymorphisms of MTHFR, GSTP1,ERCC1correlates with the clinical response to FOLFOX chemotherapy and thegenetype detected by the HRM-SNP method may be a predictor ofsensitivity to FOLFOX chemotherapy. |
